Trial Details
COMPLETEDBasic Information
| Clinical ID | c1454 |
|---|---|
| Identifier | NCT00488631 |
| Trial Title | An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Colitis, Ulcerative |
| Interventions | BIOLOGICAL: Placebo|BIOLOGICAL: Golimumab 50 mg|BIOLOGICAL: Golimumab 100 mg|BIOLOGICAL: Golimumab 200 mg |
Participant Information
| Sponsor | Janssen Research & Development, LLC |
|---|---|
| City | Birmingham |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2025-09-07 |
|---|---|
| Primary Completion Date | 2025-10-11 |
| Completion Date | 2025-02-15 |